



SPECIAL AUTHORITY REQUEST
ELBASVIR PLUS GRAZOPREVR WITH OR WITHOUT RIBAVIRIN (RBV) FOR CHRONIC HEPATITIS C

For up to date criteria and forms, please check: www.gov.bc.ca/pharmacarespecialauthority

Fax requests to 1 800 609-4884 (toll free) OR mail requests to: PharmaCare, Box 9652 Stn Prov Govt, Victoria, BC V8W 9P4

This facsimile is Doctor-Patient privileged and contains confidential information intended only for PharmaCare. Any other distribution, copying or disclosure is strictly prohibited. If you have received this fax in error, please write "MIS-DIRECTED" across the front of the form and fax toll-free to 1 800 609-4884, then destroy the pages received in error.

If PharmaCare approves this Special Authority request, approval is granted solely for the purpose of covering prescription costs. PharmaCare approval does not indicate that the requested medication is, or is not, suitable for any specific patient or condition.

Forms with information missing will be returned for completion. If no prescriber fax or mailing address is provided, PharmaCare will be unable to return a response.

Restricted to:

- Gastroenterologist Infectious Disease Specialist Other physician experienced with treating chronic Hepatitis C

SECTION 1 - PRESCRIBER INFORMATION

Name and mailing address, Mail confirmation, College ID or MSP number, Phone number, Prescriber's fax number, Critical for a timely response

SECTION 2 - PATIENT INFORMATION

Patient (family) name, Patient (given) name(s), Date of birth, Date of application, Personal health number (PHN), Critical for processing

SECTION 3 - BACKGROUND DIAGNOSTIC INFORMATION

For the treatment of patients with Chronic Hepatitis C genotype 1 or 4 who meet all the following criteria:

- Genotype has been confirmed and a copy of the genotype report is attached. For treatment-experienced patients, genotype must be from post-treatment course. For genotype 1, genotype report must be dated May 2012 or later.
Patient has compensated liver disease (i.e. with no cirrhosis or with compensated cirrhosis). Compensated cirrhosis is defined as cirrhosis with a Child Pugh score = A (5-6).
Detectable levels of hepatitis C virus (HCV RNA) in the last twelve months and a copy of the quantitative HCV RNA report is attached.
Stage of fibrosis has been evaluated within ONE year by one of the following methods:
Transient elastography (kPa)
APRI score
Liver biopsy confirmed
Copy of most recent bloodwork (i.e. CBC, AST, ALT, bilirubin, albumin) and report confirming fibrosis stage (if applicable) is attached

Not eligible for coverage:

- 1. Patients who are at high risk for non-compliance.
2. Patients who are currently being treated with another HCV direct-acting antiviral agent

PATIENT NAME	PHN	DATE (YYYY / MM / DD)
--------------	-----	-----------------------

SECTION 4 (CHOOSE FROM EITHER OPTION A OR OPTION B)

A. GENOTYPE 1:
Elbasvir plus Grazoprevir: Coverage is up to a maximum of 12 weeks. No renewals.

Genotype 1a or 1b¹ treatment-naive
 Genotype 1a or 1b, treatment-experienced (prior RELAPSERS²)
 Genotype 1b treatment-experienced (prior on-treatment virologic failures³)

OR
Elbasvir plus Grazoprevir with Ribavirin: 16 weeks (Coverage is for a maximum of 16 weeks. No renewals.)

Genotype 1a treatment-experienced (prior on-treatment virologic failures³)

OR

B. GENOTYPE 4:
Elbasvir plus Grazoprevir: 12 weeks (Coverage is for a maximum of 12 weeks. No renewals.)

Treatment-naive
 Treatment-experienced (prior RELAPSERS²)

OR
Elbasvir plus Grazoprevir with Ribavirin: 16 weeks (Coverage is for a maximum of 16 weeks. No renewals.)

Treatment-experienced (prior on-treatment virologic failures³)

NOTES:

1. PharmaCare may consider 8 weeks of coverage in treatment-naive genotype 1b patients without significant fibrosis or cirrhosis as determined by liver biopsy (i.e. Metavir F0 - F2) or by non-invasive tests.
2. Prior relapsers are patients who have previously been treated with pegIFN/RBV with or without HCV protease inhibitors and had undetectable HCV RNA at the end of previous treatment, but with subsequent detectable HCV RNA during follow-up.
3. Prior on-treatment virologic failures are patients who have previously been treated with pegIFN/RBV with or without HCV protease inhibitors and had NULL response, PARTIAL response, virologic breakthrough or rebound.

SECTION 5 – ADDITIONAL COMMENTS

Personal information on this form is collected, used and disclosed under the authority of, and in accordance with, the *British Columbia Pharmaceutical Services Act* and *Freedom of Information and Protection of Privacy Act*. It will not be disclosed to any persons without the patient's consent. The information you provide will be relevant to and used solely to (a) provide PharmaCare benefits for the medication requested, (b) to implement, monitor and evaluate this and other Ministry programs, and (c) to manage and plan for the health system generally. If you have any questions about the collection or use of this information, call Health Insurance BC from Vancouver at 1-604-683-7151 or from elsewhere in BC toll free at 1-800-663-7100 and ask to consult a pharmacist concerning the Special Authority process.

I have discussed with the patient that the purpose of releasing their information to PharmaCare is to obtain Special Authority for prescription coverage and for the purposes set out here.

 Prescriber's Signature (Mandatory)

PharmaCare may request additional documentation to support this Special Authority request.

Actual reimbursement is subject to the rules of a patient's PharmaCare plan, including any annual deductible requirement, and to any other applicable PharmaCare pricing policy.

PHARMACARE USE ONLY

STATUS	EFFECTIVE DATE (YYYY / MM / DD)	DURATION OF APPROVAL
--------	---------------------------------	----------------------